Bluebird Bio CEO defends $1.8 million price for gene therapy — 'It's really thinking about it differently'
June 14, 2019 at 15:01 PM EDT
Bluebird Bio's $1.8 million gene therapy, Zynteglo, is the second most expensive drug in the world behind Novartis' $2.1 million gene therapy for spinal muscular atrophy.
